Spyre Therapeutics, Inc. reported $0 in revenue and a $155.2M net loss for fiscal 2025. See the full SYRE financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

[EFFECT] Spyre Therapeutics, Inc. SEC Filing

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

EFFECT

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/05/2026 - 12:15 AM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date:	March 4, 2026

Accession Number:

0001628280-26-012785

Submission Type:

POS AM

CIK:	0001636282
Company Name:	Spyre Therapeutics, Inc.
File Number:	333-285341

Source: View Original Filing on SEC EDGAR